SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Mirum Pharmaceuticals, Inc. (MIRM) has a negative trailing P/E of -208.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 51.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.48%, forward earnings yield 1.93%. PEG 0.50 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (52/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 51.8 — analysts expect a return to profitability with estimated EPS of $1.87 for FY2028.
- PEG Ratio 0.50 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -0.48% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 1.93% as earnings recover.
- Analyst consensus target $116.70 (+20.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 52/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
52/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MIRM
Valuation Multiples
P/E (TTM)-208.0
Forward P/E51.8
PEG Ratio0.50
Forward PEG0.50
P/B Ratio15.44
P/S Ratio9.32
EV/EBITDA349.8
Per Share Data
EPS (TTM)$-0.47
Forward EPS (Est.)$1.87
Book Value / Share$6.27
Revenue / Share$10.39
FCF / Share$1.09
Yields & Fair Value
Earnings Yield-0.48%
Forward Earnings Yield1.93%
Dividend Yield0.00%
SharesGrow IV$1,392.61 (+1337.2%)
Analyst Target$116.70 (+20.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2018 |
-17.5 |
0.00 |
-29.42 |
0.00 |
- |
| 2019 |
-10.7 |
-0.05 |
4.32 |
0.00 |
- |
| 2020 |
-4.3 |
-0.05 |
2.56 |
0.00 |
- |
| 2021 |
-5.8 |
0.18 |
4.02 |
25.27 |
- |
| 2022 |
-4.9 |
-0.11 |
4.65 |
8.56 |
- |
| 2023 |
-7.4 |
29.62 |
4.85 |
6.48 |
- |
| 2024 |
-22.3 |
0.42 |
8.71 |
5.83 |
- |
| 2025 |
-169.7 |
2.28 |
12.60 |
7.61 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.75 |
$0.00 |
$-17.35M |
- |
| 2019 |
$-2.29 |
$0.00 |
$-52.55M |
- |
| 2020 |
$-4.09 |
$0.00 |
$-103.27M |
- |
| 2021 |
$-2.77 |
$19.14M |
$-83.99M |
-438.9% |
| 2022 |
$-4.01 |
$77.06M |
$-135.67M |
-176% |
| 2023 |
$-4.00 |
$186.37M |
$-163.42M |
-87.7% |
| 2024 |
$-1.85 |
$336.89M |
$-87.94M |
-26.1% |
| 2025 |
$-0.47 |
$521.31M |
$-23.36M |
-4.5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-1.62 |
$-2.58 – $-0.38 |
$644.92M |
$632.54M – $656.1M |
8 |
| 2027 |
$-0.06 |
$-1.02 – $0.79 |
$787.31M |
$720.78M – $854.54M |
7 |
| 2028 |
$1.87 |
$-0.16 – $4.55 |
$997.44M |
$997.44M – $997.44M |
7 |
| 2029 |
$4.99 |
$4.60 – $5.31 |
$1.29B |
$1.21B – $1.35B |
2 |
| 2030 |
$7.74 |
$7.14 – $8.25 |
$1.6B |
$1.51B – $1.69B |
5 |
